HARRY H. PENNER, JR. - Corporate Board Profile

Celldex Therapeutics, Inc.

Filing Date	Source Excerpt
2006-04-19	Harry H. Penner, Jr. Mr. Penner has been a director since January 1997. ... The Board of Directors has established an Audit Committee consisting of Peter A. Sears, Chairman, Harry H. Penner, Jr., and Larry Ellberger. ... The Board of Directors has established a Nominating and Corporate Governance Committee consisting of Karen Shoos Lipton, Chairman, Harry H. Penner, Jr., and Peter A. Sears. ... Directors who are not employees of AVANT are each entitled to receive a retainer fee of $15,000 each fiscal year.
2007-04-20	Harry H. Penner, Jr. Mr. Penner has been a director since January 1997. He is currently Chairman, Chief Executive Officer and a director of Marinus Pharmaceuticals, Inc. ... The Board of Directors has established an Audit Committee consisting of Peter A. Sears, Chairman, Harry H. Penner, Jr., and Larry Ellberger.
2008-08-25	Harry H. Penner, Jr. has been a director of AVANT since January 1997 and was Chairman of AVANT prior to the Merger with Celldex. ... The Board of Directors has established an Audit Committee currently consisting of Larry Ellberger, Chairman, Harry H. Penner, Jr., and George O. Elston. ... The Board of Directors has established a Compensation Committee currently consisting of Dr. Rajesh B. Parekh, Chairman, Harry H. Penner, Jr. and Charles R. Schaller. ... Directors who are not employees of AVANT are each entitled to receive a retainer fee of $20,000 each fiscal year. ... This table summarizes the annual cash compensation for AVANTs non-employee directors during 2007. Harry H. Penner, Jr. $43,750 ...
2009-11-06	Harry H. Penner, Jr. Age 64 Year First Became Director 1997. The Board of Directors has established an Audit Committee currently consisting of George O. Elston, Chairman, Larry Ellberger and Harry H. Penner, Jr. The Board of Directors has established a Compensation Committee currently consisting of Dr. Rajesh B. Parekh, Chairman, Harry H. Penner, Jr. and Charles R. Schaller. The Director Compensation table shows Harry H. Penner, Jr. with total compensation of $168,089.
2010-08-04	Harry H. Penner, Jr. has been a director of Celldex since January 1997. The Board of Directors has established an Audit Committee currently consisting of George O. Elston, Chairman, Larry Ellberger, and Harry H. Penner, Jr. The Board of Directors has established a Compensation Committee currently consisting of Dr. Rajesh B. Parekh, Chairman, Harry H. Penner, Jr. and Charles R. Schaller. The following table summarizes the annual compensation for our non-employee directors during 2009. Harry H. Penner, Jr. 90,000 Fees Earned or Paid in Cash, 8,960 Stock Awards, Total 98,960.
2011-04-26	Harry H. Penner, Jr. has been a director of Celldex since January 1997. The Board of Directors has established an Audit Committee currently consisting of George O. Elston, Chairman, Larry Ellberger, and Harry H. Penner, Jr. The Board of Directors has established a Compensation Committee currently consisting of Dr. Rajesh B. Parekh, Chairman, Karen Shoos Lipton and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2010. Harry H. Penner, Jr. 90,000 Fees Earned or Paid in Cash, 7,920 Stock Awards, Total 97,920.
2012-04-24	Harry H. Penner, Jr. has been a director of Celldex since January 1997 and was Chairman of AVANT prior to the consummation of the AVANT Merger. The Board of Directors has established an Audit Committee currently consisting of George O. Elston, Chairman, Larry Ellberger, and Harry H. Penner, Jr. The Board of Directors has established a Compensation Committee currently consisting of Karen L. Shoos, Chairman, George O. Elston and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2011. Harry H. Penner, Jr. Fees Earned or Paid in Cash $90,000 Stock Awards $6,480 Total $96,480
2013-04-23	Harry H. Penner, Jr. has been a director of Celldex since January 1997 and was Chairman of AVANT prior to the consummation of the AVANT Merger. The Board of Directors has established an Audit Committee currently consisting of George O. Elston, Chair, Larry Ellberger, and Harry H. Penner, Jr. The Board of Directors has established a Compensation Committee currently consisting of Karen L. Shoos, Chair, George O. Elston and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2012. Harry H. Penner, Jr. Fees Earned or Paid in Cash $90,000 Stock Awards $9,000 Total $99,000
2014-04-09	Harry H. Penner, Jr. 68 1997 The Board of Directors has established an Audit Committee currently consisting of George O. Elston, Chair, Larry Ellberger, and Harry H. Penner, Jr. The Board of Directors has established a Compensation Committee currently consisting of Karen L. Shoos, Chair, George O. Elston and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2013. Harry H. Penner, Jr. 90,000 30,400 19,481 139,881
2015-04-23	Harry H. Penner, Jr. has been a director of Celldex since January 1997. The Board of Directors has established an Audit Committee currently consisting of George O. Elston, Chair, Larry Ellberger, and Harry H. Penner, Jr. The Compensation Committee currently consists of Karen L. Shoos, Chair, George O. Elston, Harry H. Penner, Jr. and Richard van den Broek. The following table summarizes the annual compensation for our non- employee directors during 2014. Harry H. Penner, Jr. Fees Earned or Paid in Cash $90,000 Stock Awards $26,900 Option Awards $17,370 Total $134,270.
2016-04-21	Harry H. Penner, Jr. Age 70 Year First Became Director 1997. Mr. Penner is member of the Audit and Compensation Committees. Director Compensation Table shows total compensation $415,975.
2017-04-28	Harry H. Penner, Jr. has been a director of Celldex since January 1997. The Board of Directors has established an Audit Committee currently consisting of George O. Elston, Chair, Larry Ellberger and Harry H. Penner, Jr. The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2016. Harry H. Penner, Jr. Fees Earned or Paid in Cash $78,750 Stock Awards $47,200 Option Awards $47,256 Total $173,206
2018-04-30	Harry H. Penner, Jr. Age 72 Year First Became Director 1997 The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, Larry Ellberger and Harry H. Penner, Jr. The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2017. Harry H. Penner, Jr. Fees Earned or Paid in Cash $80,347 Stock Awards $23,200 Option Awards $23,345 Total $126,892
2019-04-26	Harry H. Penner, Jr. has been a director since January 1997. He serves on the Audit Committee and Compensation Committee. Compensation for 2018 was $93,594.
2020-04-28	Harry H. Penner, Jr. has been a director of Celldex since January 1997. The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2019. Harry H. Penner, Jr. received $53,750 in fees and $9,386 in option awards, totaling $63,136.
2021-04-27	Harry H. Penner, Jr. has been a director of Celldex since January 1997 and was Chairman of AVANT prior to the consummation of the AVANT Merger. Mr. Penner has served as Chairman and Chief Executive Officer of Nascent BioScience, LLC, a firm engaged in the creation and development of new life science companies since 2001. ... The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. ... The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. ... The following table summarizes the annual compensation for our non-employee directors during 2020. Harry H. Penner, Jr. Fees Earned or Paid in Cash $53,750 Option Awards $87,586 Total $141,336.
2022-04-26	Harry H. Penner, Jr. has been a director of Celldex since January 1997 and was Chairman of AVANT prior to the consummation of our merger with AVANT. ... The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. ... The Board of Directors has established a Compensation Committee currently consisting of James J. Marino, Chair, Herbert J. Conrad and Harry H. Penner, Jr. ... The following table summarizes the annual compensation for our non-employee directors during 2021. ... Harry H. Penner, Jr. Fees Earned or Paid in Cash ($) 53,750 Option Awards ($) 260,828 Total ($) 314,578.
2023-04-25	Harry H. Penner, Jr. 77 1997 1 The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. The Board of Directors has established a Compensation and Organization Development Committee currently consisting of James J. Marino, Chair, Cheryl L. Cohen and Harry H. Penner, Jr. The following table summarizes the annual compensation for our non-employee directors during 2022. Harry H. Penner, Jr. Fees Earned or Paid in Cash ($) 58,679 Option Awards ($) 231,866 Total ($) 290,545
2024-04-25	The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner, Jr. ... The amounts in the Option Awards column reflect the grant date fair value in accordance with U.S. GAAP of stock option awards made in 2023 to each of our non-employee directors for awards pursuant to the 2021 Incentive Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject to risk of forfeiture (so long as the director remains a member of the Board as of such date).